Update your tester profile Login
  • Register with Our Database

    Get started on the volunteer process by registering your basic information with our database. This information is provided to help us determine your eligibility for current and future studies.

    If you have registered with Prism in the past, please call Dayna 651-724-5047 to update your profile or learn about available studies. 


    Thanks for your interest, you'll find the intake form here

     Unfortunately at this time, Prism can not allow volunteers who live over 200 miles away to participate in research studies. If you live out of state or over 200 miles away please call Geoff at 651-641-2911 with questions. 

    We will not share or sell this info with any third party.

  • Connect With Prism Research on Social Media

    You can WIN TICKETS VIA Prism's Facebook page!

    Have you LIKED Prism Clinical Research on Facebook?

    Have you TAGGED Prism Clinical Research on Twitter?

    Have you FOLLOWED Prism Clinical Research on Instagram?

     

    Use the link below:↓

    https://www.facebook.com/PrismResearch/

  • Refer Your Friends & Family to Participate

    Simply help us get the word out about Prism Clinical Research and we’ll give you $100 for every friend you refer that completes a study.

    It’s that easy! Make money with each referral, and there’s no limit to how many friends you can refer!

    Rules:

    • Subject must complete the study.
    • Subject may not be referred more than one time.
    • Subjects may not refer each other.
    • Subject must complete the study before payment can be received.
    • Subjects eligible for Referral: (1) Must not be in Prism Clinical Research database; (2) Must not have participated in any study at Prism.
    • In the event that a subject is referred by multiple people, the first person who referred will receive payment.
    • Eligibility will be determined by Prism. Prism reserves the right to revise or eliminate this program at any time without notice.

     

     

  • Let's Talk About Endometriosis

    Prism Research has upcoming studies for individuals diagnosed with moderate to severe Endometriosis.  These studies will help determine how an investigational drug is broken down and removed from the body.

     If you or someone you know has been diagnosed with endometriosis and are interested in being considered for these studies, please contact Dayna at 651-724-5047 or register with our database and we will call you. Financial compensation for study participation ranges from $225-$2600.

    Let's Talk 

    Please contact Dayna at 651-724-5047 or daynas@prismresearchinc.com

     

     

  • Diagnosed with Celiac Disease?

    Prism Research has upcoming studies for individuals who have been diagnosed with Celiac Disease.  These FDA approved studies will help determine how an investigational drug being developed for Celiac Disease is broken down and removed from the body in volunteers diagnosed with Celiac Disease.

    If you or someone you know has been diagnosed with Celiac Disease and are interested in being considered for these studies, please contact Dayna at 651-724-5047 or register with our database and we will call you. Participants who qualify will receive a no cost health evaluation in addition to financial compensation for study participation time.

    Please contact Dayna at 651-724-5047 or daynas@prismresearchinc.com for more information on these upcoming studies for individuals diagnosed with Celiac Disease.

    Upcoming Study: 1803

    Cour Pharmeceuticals New Drug

     

  • Diagnosed with Liver Impairment?

    Prism Research has upcoming studies for individuals diagnosed with liver impairment.  These studies will help determine how an investigational drug is broken down and removed from the body in volunteers with various degrees of liver impairment when compared to volunteers with normal liver function.

     If you or someone you know has been diagnosed with liver impairment and are interested in being considered for these studies, please contact Dayna at 651-724-5047 or register with our database and we will call you. Financial compensation for study participation ranges from $400-$3500.

    Please contact Dayna at 651-724-5047 or daynas@prismresearchinc.com

    Upcoming Study: 1801

  • Diagnosed with Kidney Impairment?

    Prism Research has upcoming studies for individuals diagnosed with kidney impairment.  These studies will help determine how an investigational drug is broken down and removed from the body in volunteers with various degrees of kidney impairment when compared to volunteers with normal kidney function.

     If you or someone you know has been diagnosed with kidney impairment and are interested in being considered for these studies, please contact Lindsay at 651-368-3360 or register with our database and we will call you. Financial compensation for study participation ranges from $400-$3500.

    Please contact Lindsay at 651-368-3360 or lindsayd@prismresearchinc.com

  • Healthy: Clinical Research Study 1808

     

    Stool Sample Study

    Clinical RESEARCH study: 1808

     

    PRISM CLINICAL RESEARCH

     

    Purpose:

    •  Collection of stool samples to enable the screening/testing of a large number of compounds to determine their effect on digestive system microbiota outside the normal, living organism.

     

     GENERAL STUDY REQUIREMENTS:

     

    •  Healthy Men and Women between 18 and 79 years of age and a BMI between 17.0 to 39.9 kg/m2.
    •  Medical conditions must be stable in the opinion of the study doctor.
    •  Volunteers following a vegan or vegetarian diet are eligible to participate in this study.

      STUDY DURATION:

     

    •  There are no in Clinic Stays for this study.
    •  Return Clinic Visits: There may be up to 2 return clinic visits, including screening, if a stool sample cannot be provided by the volunteer on the day of their screening.
    •  Total study duration is approximately 1 - 14 days (including screening).

     

      METHOD OF ADMINISTRATION:

     

    •  This is a sample collection study; no study drug will be administered.

     

      STUDY COMPENSATION: 

    •  Compensation for Study Participation Time Up To: $190.00

     

     RECRUITMENT CONTACT:

     

     

     

     

     

     

     

  • Study 1708: Male and Female Participants with Migraine

    Research Purpose: Study 1708 is designed to evaluate the cognitive effects in participants receiving topiramate for prophylactic treatment of migraine comparing immediate release versus extended release formulations. Participants will receive dosings of both FDA approved formulations of topiramate.

     The following will be evaluated:

    • The effect of multiple doses of topiramate (immediate release and extended release) on cognition in participants with migraine.

    Minimum Screening Qualifications:

    Males

    Men are allowed to participate

    Females

    Women who are not pregnant, considering becoming pregnant, breast feeding or lactating are allowed to participate.  Women using acceptable forms of birth control are allowed to participate.

    Age

    18-65 years

    Body Mass Index (BMI)

    There is no body mass index requirement for this study.

    Weight

    There is no weight requirement for this study.

    Drug Testing

    Must test negative for drugs of abuse. 

    Health History

    History of episodic migraine with or without aura for at least 6 months prior to the screening visit and a frequency of 3 or more headache attacks per month during the past 3 months.

    Right hand dominant.

    On a stable dose for 3 months of a selective serotonin reuptake inhibitor for depression and/or anxiety.

    Special Requirements

    • Must be able and willing to take oral doses of the study medication at home.
    • Must have a working phone number during the entire study.

     

    Study Time Commitment: For participants who qualify based on screening evaluation, study participation will last for approximately 8 weeks.

    Inpatient Stay

    • Participants will admit to Prism Clinical Research 3 times
    • The inpatient stay is approximately 1 day one time (1 overnight) and 2 days two times  (2 overnights)

    Outpatient Visits

    • There are 3 outpatient visits during the study.
    • The outpatient visits are approximately 2 hours long. 

     

    Compensation for participation time:   Up to $­­­­­­­­­­­­­­1,660.00

    First screen: 8/28

    First Admit; 9/11

    For information regarding this study contact Kevin at 651-724-5046

  • Study 1803 (Part A): Healthy Males and Females with Celiac Disease

    Research Purpose: To evaluate an investigational drug being developed for the treatment of Celiac Disease.

    Minimum Screening Qualifications:

    Males

    Men are allowed to participate and must agree to use an acceptable form of birth control

    Females

    Women who are not breastfeeding, are not pregnant or planning to become pregnant are allowed to participate.  Women using an acceptable method of birth control are allowed to participate.

    Age

    18-75 years of age

    Weight/Body Mass Index (BMI)

    BMI between 18-25 kg/m² and weight between 72-284lbs

    Health History

    • Diagnosed by biopsy with Celiac Disease
    • Must be healthy; not being evaluated or treated for any medical conditions unless otherwise approved on a case by case basis by the study doctor.
    • No known gluten exposure for at least 10 days prior to screening visit

    Medications

    All medications will be approved on a case by case basis.

    Study Time Commitment: For participants who qualify based on screening evaluation, study participation will last for approximately 6 months, not including screening.

    Schedule

    Clinic Stay

    • Participants will admit to Prism Clinical Research 1 time.
    • The in-clinic stay will last approximately 4 days (3 overnights).

    Return Clinic Visits

    • There are 4 clinic visits
    • There are 7 phone call visits

    Compensation for participation time up to: $1,700

     

    For information regarding this study contact Dayna 651-724-5047 daynas@prismresearchinc.com 

  • Asthma: Clinical Research Study 1804

    PURPOSE:

    * To evaluate the safety and tolerability of an investigational drug in individuals diagnosed with persistent asthma who are being treated and are on a stable asthma therapy.

     

    GENERAL STUDY REQUIREMENTS:

    *Men and Women Between The age of 18 and 65

    * Individuals with Asthma on a stable Asthma Therapy

     

    STUDY DURATION:

    * 3 In-Clinic Stays: Each Lasting 4 nights/5 days

    * Return Clinic Visits: 10, Including Screening

    * Total Study Duration is Approximately 35 Weeks

     

    METHOD OF ADMINISTRATION:

    * Subcutaneous Dosing

     

    STUDY COMPENSATION:

    * Compensation for Study Participation may be granted for time and travel

     

    RECRUITMENTCONTACT:

    *  Dayna 651-724-5047 or daynas@prismresearchinc.com

  • Study 1710 (Part 2): Individuals with Moderate Renal Impairment

    Research Purpose: To determine whether the investigational drug displays the clinical safety profile to support further development in patients with moderately impaired renal function.

    Minimum Screening Qualifications:

    Males

    Men are allowed to participate

    Females

    Women of non-childbearing potential are allowed to participate

    Age

    40-85 years of age

    Body Mass Index (BMI)

    Between 18-40 kg/m²

    Minimum Weight

    50 kg

    MDRD

    30-59 mL/min/1.73 m²

    Angiotensin receptor blocker (ARB)

    Must be on an ARB for at least one month prior to screening

     

    Study Time Commitment: For participants who qualify based on screening evaluation, study participation will last for approximately 13 weeks. 

    Clinic Stay

    • Individuals participating in the inpatient portion of the study will be confined at Prism Clinical Research one time during the study period for 8 days and (7 nights)

    Return Clinic Visits

    • Individuals participating in the inpatient portion of the study will return to the clinic for 4 outpatient visits (not including screening) and 1 telephone follow up call.
    • Individuals participating in the outpatient portion of this study will have 7 outpatient clinic visits (not including screening) and 1 telephone follow up call.

     

    Screenings begin:10/23/2017

    Anticipated start date for Study 1710 (Part 2): 6Nov2017

    Compensation for participation time:

    • If you participate is in the inpatient portion of the study, up to $2800.00 upon completion of all clinic visits and follow-up phone call.
    • If your participation does not require you to participate in the inpatient portion of the study, up to $1075.00 upon completion of all clinic visits and follow-up phone call.

     

     

    For information regarding this study contact Kevin at: 651-724-5046 or kfitzgerald@prismresearchinc.com

     

     

  • Study 1717 Males and Females with Severe Renal Impairment

    Research Purpose: To evaluate the safety and tolerability of an investigational drug in individuals with renal impairment compared with individuals without renal impairment.

    Minimum Screening Qualifications:

    Males

    Men are allowed to participate

    Females

    Women must be postmenopausal or of non-childbearing potential

    Age

    18-75 years of age

    Body Mass Index (BMI)

    BMI between 18-40 kg/m² , and weigh a minimum of  50 kg (110 lbs)

    Tobacco/Nicotine Use

    No use of tobacco/nicotine containing products including electronic cigarettes in excess of 20 cigarettes per day or the equivalent during study participation.

    Health History

    Volunteers with severe renal impairment must be on a stable medication regimen and in good health consistent with renal impairment diagnoses.

     

    Healthy volunteers will not have renal impairment, and are not being evaluated or treated for any medical conditions unless otherwise approved on a case by case basis by the study doctor.

    Alcohol/Drug Abuse History

    No history of drug or alcohol abuse within 1 year before the check-in and negative drug screen at screening and check-in.

    Study Time Commitment: For participants who qualify based on screening evaluation, study participation will last for approximately 38 days

    Clinic Stay

    • Participants will be admitted to Prism Clinical Research.The in clinic stay will last approximately 5 days (4 overnights)

    Outpatient Visits

    • There is 1 clinic visit approximately 10 days following last dose of study drug.

    Compensation for participation time: Up to $1425.00

    For information regarding this study contact Kevin at: 651-724-5046 or kfitzgerald@prismresearchinc.com

     

  • Upcoming Studies

     

     

     Prism has a variety of upcoming studies to participate in: 

    • Studies for healthy males and females 
    • Liver Impairment (Study 1801)
    • Kidney Impairment 
    • Endometriosis- Associated Pain

    To be put on the call list and receive more information, when available, please contact Dayna at daynas@prismresearchinc.com or Lindsay at lindsayd@prismresearchinc.com.

Glossary of Terms

  • Clinical Trial/Study: Any investigation in human subjects intended to discover or verify the clinical, pharmacological, and or other pharmacodynamic effects of an investigational product(s), and/or to identify any adverse reactions to an investigational product(s) and/or to study absorption, distribution, metabolism and excretion of an investigational product(s) with the object of ascertaining its safety and/or efficacy. The terms clinical trial and clinical study are synonymous.

  • HIPAA: HIPAA is the acronym for the Health Insurance Portability and Accountability Act of 1996. The Centers for Medicare & Medicaid Services (CMS) is responsible for implementing various unrelated provisions of HIPAA. They are required to establish national standards for electronic health care transactions and national identifiers for providers, health plans, and employers. It also addresses the security and privacy of health data.

  • Informed Consent Form (ICF): A document approved by an authorized Institutional/Independent Review Board by which a subject voluntarily confirms his or her willingness to participate in a particular trial, after having been informed of all aspects of the trial that are relevant to the subject’s decision to participate.

  • Informed Consent: A process by which a subject voluntarily confirms his or her willingness to participate in a particular trial, after having been informed of all aspects of the trial that are relevant to the subject’s decision to participate. Informed consent is documented by means of a written, signed, and dated informed consent form.

  • Institutional/Independent Review Board (IRB): And independent body constituted of medical, scientific, and nonscientific members, whose responsibility it is to ensure the protection of the rights, safety and well-being of human subjects involved in a trial by, among other things, reviewing, approving, and providing continuing review of trials, protocols, amendments, and methods and materials to be used in obtaining and documenting informed consent of the trial subjects.

  • Investigational Product: A pharmaceutical form of an active ingredient or placebo being tested or used as a reference n a clinical trial including a product with a marketing authorization when used or assembled (formulated or packaged) in a way different from the approved form, or when used for an unapproved indication or when used to gain further information about an approved use.

  • Investigator: A person responsible for the conduct of the clinical trial at the trial site. If a team of individuals at a trial site conducts a trial, the investigator is the responsible leader of the team and may be called the Principal Investigator.
  • Protocol: A document that describes the objective(s), design, methodology, statistical considerations, and organization of a trial. The protocol usually also gives the background and rationale for the trial.

  • Randomization: The process of assigning trial subjects to treatment or control groups using and element of chance to determine the assignments in order to reduce bias.

  • Sponsor: An individual, company, institution, or organization that takes responsibility for the initiation, management, and/or financing of a clinical trial.

  • Subject/Participant/Volunteer: An individual who participates in a clinical trial, either as a recipient of the investigational product(s) or as a control.

 

Please provide us with your contact information (below) and will get back to you as soon as possible.

If you have a general question, check Volunteer FAQ for an answer. If you're unsure of who to contact, please visit the Contact Us page.

Cancel